Cargando…

COPD: adherence to therapy

Adherence to medical therapies is a growing issue, so much so that the World Health Organization defined it as “a new pharmacological problem”. The main factors affecting compliance are: frequency of administration, rapid onset of action, role of device. The most severe consequence of non-adherence...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanduzzi, Alessandro, Balbo, Piero, Candoli, Piero, Catapano, Giousuè A, Contini, Paola, Mattei, Alessio, Puglisi, Giovanni, Santoiemma, Luigi, Stanziola, Anna A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256899/
https://www.ncbi.nlm.nih.gov/pubmed/25485108
http://dx.doi.org/10.1186/2049-6958-9-60
_version_ 1782347646277517312
author Sanduzzi, Alessandro
Balbo, Piero
Candoli, Piero
Catapano, Giousuè A
Contini, Paola
Mattei, Alessio
Puglisi, Giovanni
Santoiemma, Luigi
Stanziola, Anna A
author_facet Sanduzzi, Alessandro
Balbo, Piero
Candoli, Piero
Catapano, Giousuè A
Contini, Paola
Mattei, Alessio
Puglisi, Giovanni
Santoiemma, Luigi
Stanziola, Anna A
author_sort Sanduzzi, Alessandro
collection PubMed
description Adherence to medical therapies is a growing issue, so much so that the World Health Organization defined it as “a new pharmacological problem”. The main factors affecting compliance are: frequency of administration, rapid onset of action, role of device. The most severe consequence of non-adherence is the increased risk of poor clinical outcome, associated with worsening of the quality of life and increase in health-care expenditure. It appears crucial to identify those COPD patients who are “poorly or not at all compliant with their treatment”. In order to evaluate adherence to the medical therapy, several methods were proposed, the most effective of which turned out to be self-reports, i.e. simple, brief questionnaires (e.g. Morisky test). To increase the likelihood of quickly identifying non-compliant patients, it may be useful to administer a simple questionnaire to naïve subjects (for example, in the waiting room before an examination) including six specific items allowing to identify the patient’s key characteristics. Depending on the answers, patients who do not comply with their pharmacological treatment may be classified as belonging to 6 phenotypes. For patients who are already under treatment it might be useful to administer another short questionnaire during follow up examination. Once the risk of non-compliance is identified, four possible types of measures can be taken: prescription-related, educational, behavioral and complex combined measures (combination of two or more actions). Therefore, while it is clear that adherence in COPD is a critical issue, it is also obvious that raising awareness on the disease and improving cooperation among specialists, general practitioners, health-care professionals, and patients is the starting point at which this evolution should immediately begin. Each medication is able to foster good compliance with the therapy, and consequently to maximize the efficacy, by virtue of its specific inhaler and its own active ingredient. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2049-6958-9-60) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4256899
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42568992014-12-06 COPD: adherence to therapy Sanduzzi, Alessandro Balbo, Piero Candoli, Piero Catapano, Giousuè A Contini, Paola Mattei, Alessio Puglisi, Giovanni Santoiemma, Luigi Stanziola, Anna A Multidiscip Respir Med Review Adherence to medical therapies is a growing issue, so much so that the World Health Organization defined it as “a new pharmacological problem”. The main factors affecting compliance are: frequency of administration, rapid onset of action, role of device. The most severe consequence of non-adherence is the increased risk of poor clinical outcome, associated with worsening of the quality of life and increase in health-care expenditure. It appears crucial to identify those COPD patients who are “poorly or not at all compliant with their treatment”. In order to evaluate adherence to the medical therapy, several methods were proposed, the most effective of which turned out to be self-reports, i.e. simple, brief questionnaires (e.g. Morisky test). To increase the likelihood of quickly identifying non-compliant patients, it may be useful to administer a simple questionnaire to naïve subjects (for example, in the waiting room before an examination) including six specific items allowing to identify the patient’s key characteristics. Depending on the answers, patients who do not comply with their pharmacological treatment may be classified as belonging to 6 phenotypes. For patients who are already under treatment it might be useful to administer another short questionnaire during follow up examination. Once the risk of non-compliance is identified, four possible types of measures can be taken: prescription-related, educational, behavioral and complex combined measures (combination of two or more actions). Therefore, while it is clear that adherence in COPD is a critical issue, it is also obvious that raising awareness on the disease and improving cooperation among specialists, general practitioners, health-care professionals, and patients is the starting point at which this evolution should immediately begin. Each medication is able to foster good compliance with the therapy, and consequently to maximize the efficacy, by virtue of its specific inhaler and its own active ingredient. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2049-6958-9-60) contains supplementary material, which is available to authorized users. BioMed Central 2014-11-22 /pmc/articles/PMC4256899/ /pubmed/25485108 http://dx.doi.org/10.1186/2049-6958-9-60 Text en © Sanduzzi et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Sanduzzi, Alessandro
Balbo, Piero
Candoli, Piero
Catapano, Giousuè A
Contini, Paola
Mattei, Alessio
Puglisi, Giovanni
Santoiemma, Luigi
Stanziola, Anna A
COPD: adherence to therapy
title COPD: adherence to therapy
title_full COPD: adherence to therapy
title_fullStr COPD: adherence to therapy
title_full_unstemmed COPD: adherence to therapy
title_short COPD: adherence to therapy
title_sort copd: adherence to therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256899/
https://www.ncbi.nlm.nih.gov/pubmed/25485108
http://dx.doi.org/10.1186/2049-6958-9-60
work_keys_str_mv AT sanduzzialessandro copdadherencetotherapy
AT balbopiero copdadherencetotherapy
AT candolipiero copdadherencetotherapy
AT catapanogiousuea copdadherencetotherapy
AT continipaola copdadherencetotherapy
AT matteialessio copdadherencetotherapy
AT puglisigiovanni copdadherencetotherapy
AT santoiemmaluigi copdadherencetotherapy
AT stanziolaannaa copdadherencetotherapy